First Look: See Why Palisade Bio (Nasdaq: PALI) is Lighting Up Our Radar Early This Morning

*Sponsored Market Crux Exclusive! First Look: See Why Palisade Bio (Nasdaq: PALI) is Lighting Up  Our Radar Right Now… Analyst Coverage: Brookline Capital Markets has issued a $38 target, which suggests a 4,041% upside potential from yesterday’s close. Limited Float: With fewer than 2.75M shares in its float, Palisade Bio (Nasdaq: PALI) could witness significant swings if demand begins to shift. Recent Recognition: Palisade Bio (Nasdaq: PALI) has shown short-term moves, including an approximate 139% move in under 24 hours. Expanding Market: The inflammatory bowel disease treatment market is projected to reach $22B in 2025 and surpass $31B by 2034. Upcoming Milestones: Palisade Bio (Nasdaq: PALI) is approaching key developments, including Phase 1 topline data expected in early 2025. Consider adding Palisade Bio (Nasdaq: PALI) to your radar while it’s still early… March 14, 2025 Dear Reader, Something came across my desk late yesterday, and let’s just say—we have all eyes on it right now. Friday, 3/14/2025 is shaping up to be an interesting one, and you’ll see why in just a second. When analysts start dropping targets that turn heads, you need to pay attention.  Right now, there’s a little-known company operating in a space projected to exceed $22B this year—yet it’s still flying under the radar… For now. Because if analysts are anywhere close to being right, that won’t be the case much longer. The name? Palisade Bio, Inc. (Nasdaq: PALI). And once you see the targets being set—including potential upsides of over 1,400% and 4,000% from yesterday’s close—you’re going to want to keep this one on your radar this morning.  Palisade Bio (Nasdaq: PALI) Gets $38 Target—Which Suggests Over 4,041% Upside Potential… Palisade Bio (Nasdaq: PALI) has a market cap of just around $2.7M, a sign that it appears to be flying under the radar—but recent analyst attention suggests that might not be the case for much longer. With less than 2.75M shares listed in its float, Palisade Bio (Nasdaq: PALI) is structured in a way that could see significant movement if demand begins to shift.  Analysts from two firms have recently initiated coverage, issuing targets that are difficult to ignore.  One of the oldest institutions on Wall Street, Ladenburg Thalmann, has issued a $14 target on Palisade Bio (Nasdaq: PALI), which suggests a potential upside of 1,425%. Meanwhile, Benzigna reports that Brookline Capital Markets has set a $38 target, which suggests a potential upside of 4,041% from yesterday’s $.9175 close. Palisade Bio (Nasdaq: PALI) has been trending near or above several key moving averages, showing signs that the potential for momentum may be building. 5-Day: 0.9163 20-Day: 0.9088 With its 50-Day moving average at 1.3034, 100-Day at 1.8871, and 200-Day at 2.9383, we have all eyes on Palisade Bio (Nasdaq: PALI) this morning—Friday, 3/14/2025. Just take a look at some of Palisade Bio, Inc. (Nasdaq: PALI)’s recent overnight and multi-day moves: +139% Approx. Move: 12/11/2024 → 12/12/2024 (From $1.38 to $3.30) +46% Approx. Move: 03/04/2025 → 03/12/2025 (From $0.75 to $1.10) +37% Approx. Move: 01/03/2025 → 01/06/2025 (From $1.78 to $2.44) Keep reading to see why Palisade Bio (Nasdaq: PALI) is topping our watchlist this morning. Palisade Bio (Nasdaq: PALI) Is Advancing Biopharma Research In An Expanding Market… Palisade Bio (Nasdaq: PALI) is a biopharmaceutical company focused on developing precision therapies for immune, inflammatory, and fibrotic diseases—areas where current treatment options often fall short. The company’s lead program, PALI-2108, is designed to target ulcerative colitis (UC), a chronic inflammatory condition affecting a large patient population worldwide.  With a gut-restricted mechanism of action, PALI-2108 aims to provide a more targeted approach with fewer systemic side effects compared to existing treatments. Palisade Bio (Nasdaq: PALI) isn’t stopping there.  The company is also advancing PALI-1908, an early-stage therapy designed for fibrostenotic Crohn’s disease, another severe gastrointestinal condition. With a growing market and an expanding pipeline of next-generation therapies, Palisade Bio (Nasdaq: PALI) is working to establish itself as a key player in the biotech space. A Booming Market: IBD Treatments Projected To Reach $31B By 2034 The demand for better treatments in this space isn’t just increasing—it’s accelerating at a pace that’s hard to ignore.  The global inflammatory bowel disease (IBD) treatment market is projected to push past $22B in 2025 and expand beyond $31B by 2034, reflecting the growing need for more advanced and effective solutions.  In the U.S. alone, spending is expected to approach $10B next year, driven by a combination of factors reshaping the healthcare landscape. A steady rise in ulcerative colitis and Crohn’s disease cases has placed a spotlight on the urgent need for improved therapies, as countless individuals continue to struggle with these chronic conditions.  At the same time, the demand for safer, more effective treatment options is driving innovation, with researchers and biotech companies racing to develop solutions that provide better outcomes with fewer side effects.  Breakthrough advancements in medical technology and precision medicine are also transforming the way these diseases are treated, allowing for more targeted approaches that could revolutionize patient care. With the market rapidly expanding and innovation pushing the boundaries of what’s possible, companies developing next-generation therapies are stepping into focus.  As the healthcare industry seeks to address these growing challenges, the spotlight is shifting toward those working on novel treatments—because the need for cutting-edge solutions has never been more urgent. Could Machine Learning And Targeted Therapies Could Give Palisade Bio (Nasdaq: PALI) An Edge? Palisade Bio (Nasdaq: PALI) isn’t following the conventional playbook when it comes to treatment development.  Rather than relying on broad, systemic approaches, the company is using precision medicine and machine learning to create targeted solutions designed to work where they’re needed most. Its lead candidate, PALI-2108, is a gut-restricted PDE4 inhibitor, specifically designed to focus on the affected area without unnecessary exposure to the rest of the body.  This approach aims to reduce side effects while enhancing effectiveness, addressing a critical need in the treatment of inflammatory conditions. Adding another layer of innovation, Palisade Bio (Nasdaq: PALI) is incorporating machine learning to refine patient selection.  By analyzing biomarkers, the company is working to identify those most likely to benefit from its therapies, increasing the chances of success.  With a strategy centered on precision and personalization, PALI-2108 is positioning itself as a potential breakthrough in the evolving IBD treatment market. Upcoming Milestones That Could Put Palisade Bio, Inc. (Nasdaq: PALI) in the Spotlight… Palisade Bio, Inc. (Nasdaq: PALI)’s clinical progress is accelerating, with key milestones expected over the next 12 months: Phase 1 trials for PALI-2108 → All five cohorts have been dosed, with topline data expected in the first half of 2025. Phase 1b/2a trials planned → The next step in clinical development, with potential regulatory advancements ahead. Pipeline expansion → Additional therapies targeting immune, inflammatory, and fibrotic diseases are in development. With multiple catalysts on the horizon, Palisade Bio (Nasdaq: PALI) has entered a phase where the potential for momentum could build quickly. Here’s 5 Reasons Why Palisade Bio (Nasdaq: PALI) is Topping Our Watchlist Early This Morning… 1. Upcoming Milestones: Palisade Bio (Nasdaq: PALI) is approaching key catalysts, including Phase 1 topline data expected in early 2025, Phase 1b/2a trials planned, and additional pipeline developments underway. 2. Analyst Coverage: Brookline Capital Markets has set a $38 target, which suggests an upside potential of 4,041%, while Ladenburg Thalmann has issued a $14 target, which suggests an upside potential of 1,425% for Palisade Bio, Inc. (Nasdaq: PALI). 3. Limited Float: With less than 2.75M shares in its float, Palisade Bio (Nasdaq: PALI) is structured in a way that could see significant movement if demand shifts. 4. Recent Market Recognition: Palisade Bio (Nasdaq: PALI) has shown multiple short-term moves, including an (approx.) 139% move in under 24 hours, a 46% (approx.) move in under 7 sessions and 37% (approx.) move from one session to the next.  5 Expanding Market: The inflammatory bowel disease treatment market, where Palisade Bio (Nasdaq: PALI) is developing next-generation therapies, is projected to reach $22B in 2025 and grow beyond $31B by 2034, with the U.S. market alone expected to approach $10B in 2025. Consider Getting Palisade Bio (Nasdaq: PALI) On Your Radar  While It’s Still Early… Let’s be honest—biotech companies with low floats, recent analyst attention, and key developments on the horizon don’t stay in the shadows forever. With fewer than 2.75M shares in its float, multiple short-term moves, and analysts setting targets that point to substantial upside potential, Palisade Bio (Nasdaq: PALI) is starting to look like one company that won’t be flying under the radar much longer. We have (PALI) at the top of our screens right now and are watching it very closely this morning. Consider taking a look at (PALI) while it’s still early. Don’t miss my next update—it should be on its way to you within an hour or so. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 03/11/2025 and ending on 03/14/2025 to publicly disseminate information about (PALI:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC, or their members own shares of (PALI:US). Please see important disclosure information here: https://marketcrux.com/disclosure/pali/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice